Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer.

Notch signaling, a key regulator of stem cells, is frequently overactivated in cancer. It is often linked to aggressive forms of cancer, evading standard treatment highlighting Notch as an exciting therapeutic target. Notch is in principle "druggable" by γ-secretase inhibitors (GSIs), inhibitory peptides and antibodies, but clinical use of Notch inhibitors is restricted by severe side effects and there is a demand for alternative cancer-targeted therapy. Here, we present a novel approach, using imagable mesoporous silica nanoparticles (MSNPs) as vehicles for targeted delivery of GSIs to block Notch signaling. Drug-loaded particles conjugated to targeting ligands induced cell-specific inhibition of Notch activity in vitro and exhibited enhanced tumor retainment with significantly improved Notch inhibition and therapeutic outcome in vivo. Oral administration of GSI-MSNPs controlled Notch activity in intestinal stem cells further supporting the in vivo applicability of MSNPs for GSI delivery. MSNPs showed tumor accumulation and targeting after systemic administration. MSNPs were biocompatible, and particles not retained within the tumors, were degraded and eliminated mainly by renal excretion. The data highlights MSNPs as an attractive platform for targeted drug delivery of anticancer drugs with otherwise restricted clinical application, and as interesting constituents in the quest for more refined Notch therapies.

[1]  Minhong Yan,et al.  Chronic DLL4 blockade induces vascular neoplasms , 2010, Nature.

[2]  S. Artavanis-Tsakonas,et al.  Notch signaling: cell fate control and signal integration in development. , 1999, Science.

[3]  Yiyu Dong,et al.  Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. , 2010, Cancer research.

[4]  U. Lendahl,et al.  Notch signaling mediates hypoxia-induced tumor cell migration and invasion , 2008, Proceedings of the National Academy of Sciences.

[5]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[6]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[7]  P. Majumder,et al.  Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. , 2009, Blood.

[8]  Chindo Hicks,et al.  Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. , 2008, Cancer research.

[9]  Juan L. Vivero-Escoto,et al.  Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. , 2008, Advanced drug delivery reviews.

[10]  K. Yano,et al.  Direct synthesis of monodispersed thiol-functionalized nanoporous silica spheres and their application to a colloidal crystal embedded with gold nanoparticles , 2007 .

[11]  Rasmus Niemi,et al.  Targeting of porous hybrid silica nanoparticles to cancer cells. , 2009, ACS nano.

[12]  J. Eriksson,et al.  Cancer-cell-specific induction of apoptosis using mesoporous silica nanoparticles as drug-delivery vectors. , 2010, Small.

[13]  Cecilia Sahlgren,et al.  Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles--opportunities & challenges. , 2010, Nanoscale.

[14]  L. Miele.  Rational targeting of Notch signaling in breast cancer , 2008, Expert review of anticancer therapy.

[15]  J. Eriksson,et al.  Targeted intracellular delivery of hydrophobic agents using mesoporous hybrid silica nanoparticles as carrier systems. , 2009, Nano letters.

[16]  Hiroshi Maeda,et al.  Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. , 2010, Bioconjugate chemistry.

[17]  Hans Clevers,et al.  Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells , 2005, Nature.

[18]  J. Fraser Stoddart,et al.  Mesostructured multifunctional nanoparticles for imaging and drug delivery , 2009 .

[19]  J. Rosenholm,et al.  Cancer-cell targeting and cell-specific delivery by mesoporous silica nanoparticles , 2010 .

[20]  S. Bray.  Notch signalling: a simple pathway becomes complex , 2006, Nature Reviews Molecular Cell Biology.

[21]  Iannis Aifantis,et al.  γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia , 2009, Nature Medicine.

[22]  Minhong Yan,et al.  Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis , 2006, Nature.

[23]  Thijs J. Hagenbeek,et al.  Therapeutic antibody targeting of individual Notch receptors , 2010, Nature.

[24]  Chin-Tu Chen,et al.  Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles. , 2010, Biomaterials.

[25]  S. Artavanis-Tsakonas,et al.  Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine , 2009, Proceedings of the National Academy of Sciences.

[26]  Raymond E. Moellering,et al.  Direct inhibition of the NOTCH transcription factor complex , 2009, Nature.

[27]  U. Lendahl,et al.  Cross-talk between Notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches (Cancer Research (July 1, 2008) 68 (5226-5235)) , 2008 .

[28]  Patrick Maisonneuve,et al.  Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis , 2004, The Journal of cell biology.

[29]  Raphael Kopan,et al.  The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism , 2009, Cell.

[30]  T. Yeatman,et al.  Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. , 2010, Cancer research.

[31]  Colleen Delaney,et al.  Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution , 2010, Nature Medicine.

[32]  Y. Hung,et al.  Monoclonal antibody-functionalized mesoporous silica nanoparticles (MSN) for selective targeting breast cancer cells , 2009 .

[33]  S. Artavanis-Tsakonas,et al.  Notch signals control the fate of immature progenitor cells in the intestine , 2005, Nature.

[34]  Huang-Hao Yang,et al.  An efficient cell-targeting and intracellular controlled-release drug delivery system based on MSN-PEM-aptamer conjugates , 2009 .

[35]  T. Golde,et al.  Notch signaling in cancer. , 2006, Current molecular medicine.

[36]  K. Raj,et al.  The role of Notch in tumorigenesis: oncogene or tumour suppressor? , 2003, Nature Reviews Cancer.

[37]  Michelle Bradbury,et al.  Fluorescent silica nanoparticles with efficient urinary excretion for nanomedicine. , 2009, Nano letters.

[38]  Zongxi Li,et al.  Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. , 2010, Small.

[39]  Monty Liong,et al.  Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. , 2008, ACS nano.

[40]  T. Golde,et al.  Rational targeting of Notch signaling in cancer , 2008, Oncogene.

[41]  Daniel J. Hoeppner,et al.  Notch signalling regulates stem cell numbers in vitro and in vivo , 2006, Nature.

[42]  Jay S. Fine,et al.  Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation* , 2004, Journal of Biological Chemistry.